Despite the many ergonomic advantages of perspiration (sweat) compared to other biofluids (particularly in “wearable” devices), sweat remains an underutilized source of biomarker analytes compared to the established biofluids: blood, urine, and saliva. Upon closer comparison to other non-invasive biofluids, the advantages may even extend beyond ergonomics: sweat might provide superior analyte information. Sweat has many of the same analytes and analyte concentrations found in blood and interstitial fluid. Interstitial fluid has even more analytes nearer to blood concentrations than sweat does, especially for larger sized and more hydrophilic analytes (such as proteins).
A number of challenges, however, have historically kept sweat from occupying its place among the preferred clinical biofluids. These challenges include very low sample volumes (nL to μL), unknown concentration due to evaporation, filtration and dilution of large analytes, mixing of old and new sweat, and the potential for contamination from the skin surface. More recently, rapid progress in “wearable” sweat sampling and sensing devices has resolved several of the historical challenges. However, this recent progress has been limited to high concentration analytes (μM to mM) sampled at high sweat rates (>1 nL/min/gland) found in, for example athletic applications. Progress will be much more challenging as sweat biosensing moves towards detection of large, low concentration analytes (nM to pM and lower).
Additionally, many known sensor technologies for detecting larger molecules are ill-suited for use in wearable sweat sensing devices, which require sensors that permit continuous use on a wearer's skin. Therefore, sensor modalities that require complex microfluidic manipulation, the addition of reagents, the use of limited shelf-life components, such as antibodies, or sensors that are designed for a single use will not be sufficient for sweat sensing.
Electrochemical aptamer-based (“EAB”) biosensor technology, such as is disclosed in U.S. Pat. Nos. 7,803,542 and 8,003,374, presents a stable, reliable bioelectric sensor that is sensitive to target analytes in sweat, while also being capable of multiple analyte capture events during the sensor lifespan. As disclosed in PCT/US17/23399, incorporated by reference in its entirety herein, EAB sensors for use in continuous sweat sensing are configured to provide stable sensor responses with a life cycle extensive enough for multiple analyte binding and release cycles. Such sensors include a plurality of individual aptamer sensing elements, as depicted in
With reference to
Current state of the art EAB sensors use a methylene blue (MB) molecule as a redox moiety, because its behavior is well understood, it has a suitably low redox reaction potential, and it is stable during typical electrochemical processes. In testing media with very stable and narrow pH ranges, such as blood, aptamer sensing elements using MB as the redox moiety have very consistent performance through multiple signal-on/signal-off analyte capture cycles. One challenge with the use of EAB sensor technology for sweat sensing, however, is that electrical outputs from such sensors often have a strong dependence on pH. Sweat pH is not stable, and can vary as much as 300×, from about 4.5 to about 7. Because of the nature of its redox reaction, MB's performance is very sensitive to the variation in sweat sample pH. Methylene blue's redox potential depends both on its protonation state and, as depicted in
One solution to mitigate the effect of pH variability on EAB sensor response would be to add a pH sensor and use the readings from the sensor to correct for pH-induced errors in the response. For example, integration of a pH sensor in a sweat sensing device is disclosed in PCT/US15/40113, which is hereby incorporated herein in its entirety. For many applications, however, adding sensors to correct for pH may prove inferior to buffering the biofluid sample to reduce the effects of pH variability on the EAB sensors. Devices and methods for buffering a sweat sample for pH are disclosed in PCT/US16/58357, which employ a membrane with minimal pore sizes to prevent the buffer molecules, such as phosphorus and sulfate, from traversing the membrane and contaminating the sweat sample. However, such use of a buffer membrane with minimal pore size prevents or substantially slows adequate, real time proton transfer between the buffer solution and the biofluid sample and, thus, negatively impacts the sampling rate.
Accordingly, it is desirable to have simple, yet robust devices and methods to reduce the output variability due to pH for one or more redox mediated sensors in a wearable biofluid sensing device. It is particularly desirable to have devices and methods for tuning the pH of a biofluid sample rapidly, with minimal impedance of sample flow rate, prior to reaction of the sample with one or more aptamer sensing elements. Rapid, real time tuning of biofluid sample pH, as the sample is collected, improves the accuracy and stability of the EAB sensor across multiple analyte capture cycles.
Devices and methods are described herein for tuning biofluid sample pH to enable more accurate analyte concentration measurements with pH-sensitive sensors. In the disclosed embodiments, biofluid samples react with a polymer buffering material during transfer to a sensing element. The reaction with the buffering material causes protonation or deprotonation of the sample based upon 1) the pH of the sample, and 2) the selected quantity and pKa of the functional groups in the buffering material. Controlling the H+ content of a biofluid sample has beneficial effects on the accuracy of the biofluid sensor by reducing or eliminating signal changes due to redox moiety variability, thereby isolating signal changes reflecting analyte concentration.
The objects and advantages of the disclosed invention will be further appreciated in light of the following detailed descriptions and drawings in which:
“Continuous monitoring” means the capability of a device to provide at least one measurement of biofluid determined by a continuous or multiple collection and sensing of that measurement or to provide a plurality of measurements of biofluid over time.
As used herein, “interstitial fluid” or “tissue fluid” is a solution that bathes and surrounds tissue cells. The interstitial fluid is found in the interstices between cells. Embodiments of the disclosed invention measure analytes from interstitial fluid found in the skin and, particularly, interstitial fluid found in the dermis. In some cases where interstitial fluid is emerging from sweat ducts, the interstitial fluid contains some sweat as well, or alternately, sweat may contain some interstitial fluid.
As used herein, “biofluid” may mean any human biofluid, including, without limitation, sweat, interstitial fluid, blood, plasma, serum, tears, and saliva. For sweat sensing applications as generally discussed herein, biofluid has a narrower meaning, namely, a fluid that is comprised mainly of interstitial fluid or sweat as it emerges from the skin.
As used herein, “chronological assurance” means the sampling rate or sampling interval that assures measurement(s) of analytes in a biofluid are made at the rate where measurements can be made of new biofluid analytes emerging from the body. Chronological assurance may also include a determination of the effect of sensor function, potential contamination with previously generated analytes, other fluids, or other measurement contamination sources. Chronological assurance may have an offset for time delays in the body (e.g., a well-known 5 to 30-minute lag time between analytes in blood emerging in interstitial fluid), but the resulting sampling interval (defined below) is independent of lag time, and furthermore, this lag time is inside the body, and therefore, for chronological assurance as defined above and interpreted herein, this lag time does not apply.
As used herein, “biofluid sampling rate” or “sampling rate” is the effective rate at which new biofluid, originating from pre-existing pathways, reaches a sensor that measures a property of the fluid or its solutes. Sampling rate is the rate at which new biofluid is refreshed at the one or more sensors and therefore old biofluid is removed as new fluid arrives. In one embodiment, this can be estimated based on volume, flow-rate, and time calculations, although it is recognized that some biofluid or solute mixing can occur. Sampling rate directly determines or is a contributing factor in determining the chronological assurance. Times and rates are inversely proportional (rates having at least partial units of 1/seconds), therefore a short or small time required to refill sample volume can also be said to have a fast or high sampling rate. The inverse of sampling rate (1/s) could also be interpreted as a “sampling interval(s)”. Sampling rates or intervals are not necessarily regular, discrete, periodic, discontinuous, or subject to other limitations. Like chronological assurance, sampling rate may also include a determination of the effect of potential contamination with previously generated biofluid, previously generated solutes (analytes), other fluid, or other measurement contamination sources for the measurement(s). Sampling rate can also be in part determined from solute generation, transport, advective transport of fluid, diffusion transport of solutes, or other factors that will impact the rate at which new sample will reach a sensor and/or is altered by older sample or solutes or other contamination sources.
As used herein, “sample generation rate” is the rate at which biofluid is generated by flow through pre-existing pathways. Sample generation rate is typically measured by the flow rate from each pre-existing pathway in nL/min/pathway. In some cases, to obtain total sample flow rate, the sample generation rate is multiplied by the number of pathways from which the sample is being sampled. Similarly, as used herein, “analyte generation rate” is the rate at which solutes move from the body or other sources toward the sensors.
As used herein, “measured” can imply an exact or precise quantitative measurement and can include broader meanings such as, for example, measuring a relative amount of change of something. Measured can also imply a binary measurement, such as ‘yes’ or ‘no’ type qualitative measurements.
As used herein, “sample volume” is the fluidic volume in a space that can be defined multiple ways. Sample volume may be the volume that exists between a sensor and the point of generation of biofluid sample. Sample volume can include the volume that can be occupied by sample fluid between: the sampling site on the skin and a sensor on the skin where the sensor has no intervening layers, materials, or components between it and the skin; or the sampling site on the skin and a sensor on the skin where there are one or more layers, materials, or components between the sensor and the sampling site on the skin.
“Analyte” means a substance, molecule, ion, or other material that is measured by a biofluid sensing device.
As used herein, the term “analyte-specific sensor” is a sensor specific to an analyte and performs specific chemical recognition of the analytes presence or concentration (e.g., ion-selective electrodes, enzymatic sensors, electrochemical aptamer-based sensors, etc.). For example, sensors that sense impedance or conductance of a fluid, such as sweat, are excluded from the definition of “analyte-specific sensor” because sensing impedance or conductance merges measurements of all ions in biofluid (i.e., the sensor is not chemically selective; it provides an indirect measurement). Sensors could also be optical, mechanical, or use other physical/chemical methods which are specific to a single analyte. Further, multiple sensors can each be specific to one of multiple analytes.
“EAB sensor” means an electrochemical aptamer-based biosensor that is configured with multiple aptamer sensing elements that, in the presence of a target analyte in a biofluid sample, produce a signal indicating analyte capture, and which signal can be added to the signals of other such sensing elements, so that a signal threshold may be reached that indicates the presence or concentration of the target analyte.
“Aptamer” means an aptamer, a DNA aptamer, or other suitable molecules or complexes, such as proteins, polymers, molecularly imprinted polymers, polypeptides, and glycans, that experience a conformation change in the presence of a target analyte and are capable of being used in an analyte-specific sensor.
“Sensitivity” means the change in output of the sensor per unit change in the parameter being measured. The change may be constant over the range of the sensor (linear), or it may vary (nonlinear).
“Recovery interval” means the time required for an aptamer sensing element to release a target analyte back into solution and return to its signal-off configuration.
“Signal threshold” means the combined strength of signal-on indications produced by a plurality of aptamer sensing elements that indicates the presence of a target analyte.
Referring now to the drawing figures, in which like numerals indicate like elements throughout the views, several exemplary embodiments of a biofluid sensing device and method will be described. Embodiments described herein apply to any type of biofluid sensing device that measures at least one analyte in sweat, interstitial fluid, or other biofluid. The disclosed embodiments may be applied to sensing devices which measure samples at chronologically assured sampling rates or intervals. Further, the embodiments described herein may take on many forms including patches, bands, straps, portions of clothing, wearables, or any other suitable mechanism that reliably brings sampling and sensing technology into intimate proximity with one or more biofluid samples as the sample is transported to the skin surface. While some embodiments utilize adhesives to hold a sensing device near the skin, devices could also be held by other mechanisms that hold the device secure against the skin, such as a strap or embedding in a helmet. Certain embodiments show sensors as simple individual elements. It is understood that many sensors require two or more electrodes, reference electrodes, or additional supporting technology or features which are not captured in the description herein. Sensors are preferably electrical in nature, but may also include optical, chemical, mechanical, or other known biosensing mechanisms. Sensors can be in duplicate, triplicate, or more, to provide improved data and reading accuracy. Certain embodiments of the disclosed invention show sub-components of what would be sensing devices with more conventional sub-components (such as a battery) needed for use of the device in various applications. For purposes of brevity and of greater focus on inventive aspects, such subcomponents are not explicitly shown or described herein.
Referring now to
The embodiments described herein include a buffering material for tuning the pH of a biofluid sample on exposure of the sample to the buffering material. The buffering material may comprise any individual or polyfunctional polymer chain having one or more functional groups that regularly accept or donate a hydrogen ion in response to the pH of a substance in fluidic contact with the material. The functional groups can be ionic or non-charged depending upon the pH of the biofluid sample and pKa of the selected functional groups. The buffering material will tune the sample's H+ concentration to an operative or preferred pH for the EAB sensor by protonating or deprotonating the sample, depending on whether the sample is a higher or lower pH than the buffering material. The buffering material may stabilize biofluid samples for two or more different pH levels through the use of different functional groups on the polymer chain, or by using copolymers. The functional groups may include polyprotic moieties, thereby allowing for two or more buffering regions to exist on the titration curve of the material. Samples having different pH levels can be buffered to the pH of the sensor by altering the number of protons dissociated from the sample. The selected polymer(s) will vary, depending upon the application, by altering the number of functional groups and/or the pKa values of the functional groups on the polymer chain or co-polymers. The selection of a suitable buffering material involves a balance between the desired signal from the EAB sensor, the density of the polymers, the flow rate of the biofluid sample, and the desired time resolution for the sensor.
In the device depicted in
which indicates that the rate of exchange between the buffering material and sample will depend directly upon the surface area and pore size of the membrane, and inversely on the velocity of the fluid sample past the membrane. When the biofluid sample has a pH above the pH of the buffering material 340, hydrogen ions will be transferred from molecules of the buffering polymers 360 to molecules in the biofluid sample. This H+ transfer adjusts the sample pH to the buffer pH, giving the buffering material 340 a net negative or net neutral charge. Likewise, when the biofluid sample has a pH that is lower than the pH of the buffering material 340, hydrogen ions will be removed from the sample molecules and transferred to the buffer molecules, giving the buffering material a net positive or net neutral charge. The buffering material 340 will have a much larger volume relative to the biofluid sample volume, providing sufficient capacity to stabilize biofluid samples through numerous sampling intervals, without losing the proton transfer capability of the buffer. In the embodiment depicted in
In a second embodiment, depicted in
In a third embodiment, depicted in
In another exemplary embodiment, depicted in
Alternatively, as shown in
In another exemplary embodiment, depicted in
In an additional, timed buffering embodiment, a pH sensor (not shown) at an inlet to a fluid channel measures the pH of an incoming biofluid sample. The sample pH measurement dictates a time interval for the sample to flow through the channel prior to the device reading a signal from the sensors 320, 322, 324. The greater the difference between the sample pH and the sensor pH, the greater the time interval prior to obtaining a sensor reading. Increasing the time interval provides additional time for buffering the sample within the fluid channel to achieve the desired sample pH prior to reading the sensor signal.
In each of the described embodiments, one or more polymers are selected to provide a rapid exchange of protons with a biofluid sample, in real time, as the sample is conveyed to a sensor. The devices disclosed herein improve upon previous pH buffers for EAB sensors by increasing the fluid contact between the buffer and the sample. Using a larger-sized polymer as a buffer, rather than phosphate or sulfate as used in prior known buffers, allows for larger pore size in a buffering membrane without molecules passing through the membrane and contaminating the sample. Additionally, configuring the buffer as one or more polymer chains, and affixing the polymer chains within a fluid channel or on a sensor, allows for device configurations that eliminate the buffering reservoir and membrane, while providing rapid H+ exchange between the buffer and biofluid sample to maintain the sampling rate. Eliminating the buffering reservoir and membrane reduces the bulk and complexity of the devices.
While several embodiments have been described herein, it should be apparent that various modifications, alterations, and adaptations to those embodiments may occur to persons skilled in the art with attainment of at least some of the advantages. The disclosed embodiments are therefore intended to include all such modifications, alterations, and adaptations without departing from the scope of the embodiments as set forth herein.
The present application claims priority to PCT/US18/38633, filed Jun. 20, 2018, U.S. provisional application No. 62/522,762 filed on Jun. 21, 2017, and U.S. provisional application No. 62/634,220 filed on Feb. 23, 2018, the disclosures of which are hereby incorporated herein by reference in their entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US18/38633 | 6/20/2018 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62522762 | Jun 2017 | US | |
62634220 | Feb 2018 | US |